Dataset Information

LINC00309 is associated with short disease-free survival in breast cancer.

ABSTRACT:

Background

Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict the outcome of breast cancer, especially for hormone-receptor positive patients.

Methods

This retrospective study collected 290 breast cancer patients including 161 patients with hormone-positive. qPCR was performed to detect the expression of LINC00309. Kaplan-Meier and Cox risk proportion model were applied to disclose the function of LINC00309 for breast cancer prognosis.

Results

LINC00309 high expression was an independent predictor for worse disease-free survival (HR?=?2.127; 95% CI 1.074-4.212; p?=?0.030) and associated with a shorter disease-free survival (p?=?0.027), especially in hormone-positive breast cancer patients (p?=?0.001). Also LINC00309 high expression was associated with a shorter disease-free survival both in selective estrogen receptor modulator related hormone therapy (p?=?0.025) and aromatase inhibitors related hormone therapy (p?=?0.048). Moreover, LINC00309 was an independent predictor of worse disease-free survival in hormone-receptor positive breast cancer patients on univariate (HR?=?4.505; 95% CI 1.722-11.785; p?=?0.002) and multivariate (HR?=?4.159; 95% CI 1.537-11.251; p?=?0.005) analyses.

Conclusion

In breast cancer, Linc00309 is significantly associated with poor prognosis and may represent a new marker of prognosis.

SUBMITTER: Huang S

PROVIDER: S-EPMC6686222 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

LINC00309 is associated with short disease-free survival in breast cancer.

Huang Sheng S Chi Yayun Y Chi Weiru W Guo Rong R Su Yonghui Y Xue Jingyan J Zhou Shaoqiang S Wang Jiankui J Yang Zhuangqing Z Nie Jianyun J Shao Zhimin Z Chen Dedian D Wu Jiong J

Cancer cell international 20190807

<h4>Background</h4>Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict the outcome of breast cancer, especially for hormone-receptor positive patients.<h4>Methods</h4>This retrospective study collected 290 breast cancer patients including 161 patients wi ...[more]

PMID: 31406486

Similar Datasets

Project description:BackgroundIn locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of cancer therapy, though whether it is applicable to TNBC is still unclear.MethodsA total of 14 non-pCR TNBC patients were enrolled, and tissue samples from radical operation were collected. Of these, 7 cases developed disease progression within 12 months after operation [short disease-free survival (short DFS)], while others showed longer DFS over 1 year (long DFS). Next generation sequencing (NGS) analysis targeting 422 cancer-related genes and in vitro studies were performed.ResultsA total of 72 mutations were detected within 14 patients, which ranged from 1 to 8 per patient with a median mutations number of 5. The median number of mutations in the short-DFS group was higher than that in the long-DFS group (6.0 vs. 4.3; P=0.094). Furthermore, 6 gene mutation types were detected, with missense mutations displayed in the majority (36/72, 50.0%). No correlation between mutation type and DFS was found. Among 422 cancer-related genes, alterations in 30 genes were detected. TP53 (12/14, 85.7%) was the most common mutation gene in the entire cohort. RB1 mutations significantly occurred in patients with high Ki-67 scores (P=0.013). Additionally, 4 mutations of PTPN13 (57.1%, 4/7) and 3 of JARID2 (42.9%, 3/7) were only detected in the short-DFS group, while patients with JARID2 mutation had a significantly shorter DFS period (P=0.026). Experiments in vitro confirmed that JARID2 gene was widely expressed in various breast cancer cell lines. Knockdown of JARID2 in MD-MBA-231 cells by small interfering RNA (siRNA) decreased the expression of E-cadherin, and increased the levels of vimentin, MMP7, and MMP9.ConclusionsIn non-pCR TNBC, JARID2 mutation and TMB elevated in patients with short-DFS, indicating the potential prognostic biomarkers and therapeutic molecular targets for locally advanced TNBC.

Dataset Information

LINC00309 is associated with short disease-free survival in breast cancer.

Background

Methods

Results

Conclusion

Publications

LINC00309 is associated with short disease-free survival in breast cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets